Personalis, Inc. (NASDAQ:PSNL) Stock Has Average Price Target of $14.54

Shares of Personalis, Inc. (NASDAQ:PSNL) have received a consensus recommendation of “Hold” from the ten analysts that are covering the stock, MarketBeat Ratings reports. One research analyst has rated the stock with a sell rating, five have issued a hold rating and four have issued a buy rating on the company. The average 12-month target price among analysts that have issued ratings on the stock in the last year is $14.54.

Several analysts have recently commented on PSNL shares. Zacks Research raised shares of Personalis from a “strong sell” rating to a “hold” rating in a report on Monday, September 7th. BTIG Research raised their target price on shares of Personalis from $11.00 to $16.25 and gave the stock a “buy” rating in a report on Monday, July 20th. Needham & Company LLC downgraded shares of Personalis from a “buy” rating to a “hold” rating in a research report on Monday, July 20th. TD Cowen reaffirmed a “buy” rating on shares of Personalis in a report on Wednesday, July 15th. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Personalis in a research report on Friday, July 17th.

Insider Buying and Selling

In related news, CFO Aaron Tachibana sold 2,931 shares of Personalis stock in a transaction that occurred on Friday, September 18th. The stock was sold at an average price of $16.22, for a total transaction of $47,540.82. Following the completion of the transaction, the chief financial officer directly owned 195,902 shares in the company, valued at approximately $3,177,530.44. This trade represents a 1.47% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, SVP Stephen Moore sold 2,068 shares of Personalis stock in a transaction that occurred on Friday, September 18th. The shares were sold at an average price of $16.22, for a total value of $33,542.96. Following the transaction, the senior vice president owned 90,257 shares of the company’s stock, valued at approximately $1,463,968.54. This represents a 2.24% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The sale was made to cover tax withholding obligations related to the vesting of equity awards. In the last quarter, insiders sold 116,456 shares of company stock worth $1,774,916. Corporate insiders own 4.20% of the company’s stock.

Institutional Investors Weigh In On Personalis

Hedge funds and other institutional investors have recently made changes to their positions in the company. Tidal Investments LLC acquired a new stake in shares of Personalis during the 2nd quarter worth approximately $1,146,000. WINTON GROUP Ltd acquired a new position in shares of Personalis in the 2nd quarter valued at $496,000. Engineers Gate Manager LP purchased a new stake in Personalis during the second quarter worth $1,552,000. Squarepoint Ops LLC purchased a new stake in Personalis during the second quarter worth $319,000. Finally, Arizona State Retirement System grew its position in Personalis by 28.2% during the second quarter. Arizona State Retirement System now owns 18,766 shares of the company’s stock valued at $251,000 after buying an additional 4,131 shares during the period. Institutional investors and hedge funds own 61.91% of the company’s stock.

Personalis Stock Up 0.2%

Personalis stock opened at $16.35 on Friday. The stock has a 50-day moving average price of $15.26 and a 200 day moving average price of $11.23. The company has a market capitalization of $1.71 billion, a price-to-earnings ratio of -15.00 and a beta of 2.31. Personalis has a 52 week low of $4.95 and a 52 week high of $18.89.

Personalis (NASDAQ:PSNL) last issued its quarterly earnings results on Tuesday, August 4th. The company reported ($0.30) earnings per share for the quarter, missing the consensus estimate of ($0.26) by ($0.04). Personalis had a negative return on equity of 46.47% and a negative net margin of 153.84%.The business had revenue of $22.36 million during the quarter, compared to analyst estimates of $16.69 million. Research analysts anticipate that Personalis will post -1.07 EPS for the current fiscal year.

Personalis Company Profile

Personalis, Inc is a genomics company focused on precision oncology and advanced molecular testing. The company develops and commercializes genomic products designed to help identify, monitor and characterize cancer, supporting more informed treatment decisions and the development of targeted therapies.

Its offerings include tissue- and blood-based tumor profiling, liquid biopsy testing and immune profiling. Personalis’ technologies are designed to detect and track tumor-derived signals, evaluate genomic alterations and provide insights into the interaction between cancer and the immune system.